Fase 2
Quiénes somos
Estudio de fase I/II del régimen de inmunoterapia combinada: SX-682, Vacuna TriAdeno, Retifanlimab y Agonista de IL-15 N-803 (STAR15) para el Cáncer Colorrectal Metastásico (CCRm).
Estudio para evaluar INCB099280 en participantes con tumores sólidos seleccionados que no han recibido ningún inhibidor de los puntos de control inmunitarios.
PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
KN035 for dMMR/MSI-H Advanced Solid Tumors
Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK )
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
